Optimization of influenza A vaccine virus by reverse genetic using chimeric HA and NA genes with an extended PR8 backbone.
Identifieur interne : 000628 ( PubMed/Corpus ); précédent : 000627; suivant : 000629Optimization of influenza A vaccine virus by reverse genetic using chimeric HA and NA genes with an extended PR8 backbone.
Auteurs : Julie Medina ; Houda Boukhebza ; Amélie De Saint Jean ; Régis Sodoyer ; Isabelle Legastelois ; Catherine MosteSource :
- Vaccine [ 1873-2518 ] ; 2015.
English descriptors
- KwdEn :
- Amino Acid Sequence, Animals, Antigens, Viral (genetics), Antigens, Viral (immunology), Chlorocebus aethiops, Dogs, Hemagglutinin Glycoproteins, Influenza Virus (chemistry), Hemagglutinin Glycoproteins, Influenza Virus (genetics), Hemagglutinin Glycoproteins, Influenza Virus (immunology), Humans, Influenza A Virus, H1N1 Subtype (genetics), Influenza A Virus, H1N1 Subtype (growth & development), Influenza A Virus, H1N1 Subtype (immunology), Influenza Vaccines (chemistry), Influenza Vaccines (genetics), Influenza Vaccines (immunology), Madin Darby Canine Kidney Cells, Molecular Sequence Data, Neuraminidase (genetics), Reassortant Viruses (genetics), Recombinant Fusion Proteins (chemistry), Recombinant Fusion Proteins (immunology), Reverse Genetics (methods), Sequence Alignment, Sequence Analysis, DNA, Vero Cells.
- MESH :
- chemical , chemistry : Hemagglutinin Glycoproteins, Influenza Virus, Influenza Vaccines, Recombinant Fusion Proteins.
- chemical , genetics : Antigens, Viral, Hemagglutinin Glycoproteins, Influenza Virus, Influenza Vaccines, Neuraminidase.
- chemical , immunology : Antigens, Viral, Hemagglutinin Glycoproteins, Influenza Virus, Influenza Vaccines, Recombinant Fusion Proteins.
- genetics : Influenza A Virus, H1N1 Subtype, Reassortant Viruses.
- growth & development : Influenza A Virus, H1N1 Subtype.
- immunology : Influenza A Virus, H1N1 Subtype.
- methods : Reverse Genetics.
- Amino Acid Sequence, Animals, Chlorocebus aethiops, Dogs, Humans, Madin Darby Canine Kidney Cells, Molecular Sequence Data, Sequence Alignment, Sequence Analysis, DNA, Vero Cells.
Abstract
The yield of influenza antigen production may significantly vary between vaccine strains; for example the A/California/07/09 (H1N1)-X179A vaccine virus, prepared during 2009 influenza pandemic, presented a low antigen yield in eggs compared to other seasonal H1N1 reassortants. In this study a bi-chimeric virus expressing HA and NA genes with A/Puerto Rico/8/34 (H1N1) (PR8) and X179A domains was rescued by reverse genetics using a mixture of Vero/CHOK1 cell lines (Medina et al. [7]). The bi-chimeric virus obtained demonstrated to yield much larger amounts of HA than X179A in eggs as measured by single-radial-immunodiffusion (SRID), the reference method to quantify HA protein in influenza vaccine. Such kind of optimized virus using PR8 backbone derived chimeric glycoproteins could be used as improved seed viruses for vaccine production.
DOI: 10.1016/j.vaccine.2015.06.112
PubMed: 26206270
Links to Exploration step
pubmed:26206270Le document en format XML
<record><TEI><teiHeader><fileDesc><titleStmt><title xml:lang="en">Optimization of influenza A vaccine virus by reverse genetic using chimeric HA and NA genes with an extended PR8 backbone.</title><author><name sortKey="Medina, Julie" sort="Medina, Julie" uniqKey="Medina J" first="Julie" last="Medina">Julie Medina</name><affiliation><nlm:affiliation>Department of Research and Development, Sanofi Pasteur, 1541 Avenue Marcel Mérieux, 69280 Marcy L'Etoile, France. Electronic address: julie.medina@live.fr.</nlm:affiliation></affiliation></author><author><name sortKey="Boukhebza, Houda" sort="Boukhebza, Houda" uniqKey="Boukhebza H" first="Houda" last="Boukhebza">Houda Boukhebza</name><affiliation><nlm:affiliation>Department of Research and Development, Sanofi Pasteur, 1541 Avenue Marcel Mérieux, 69280 Marcy L'Etoile, France. Electronic address: Houda.Boukhebza@sanofipasteur.com.</nlm:affiliation></affiliation></author><author><name sortKey="De Saint Jean, Amelie" sort="De Saint Jean, Amelie" uniqKey="De Saint Jean A" first="Amélie" last="De Saint Jean">Amélie De Saint Jean</name><affiliation><nlm:affiliation>Department of Research and Development, Sanofi Pasteur, 1541 Avenue Marcel Mérieux, 69280 Marcy L'Etoile, France. Electronic address: amelie.desaintjean@free.fr.</nlm:affiliation></affiliation></author><author><name sortKey="Sodoyer, Regis" sort="Sodoyer, Regis" uniqKey="Sodoyer R" first="Régis" last="Sodoyer">Régis Sodoyer</name><affiliation><nlm:affiliation>Department of Research and Development, Sanofi Pasteur, 1541 Avenue Marcel Mérieux, 69280 Marcy L'Etoile, France. Electronic address: regis.sodoyer@bioaster.org.</nlm:affiliation></affiliation></author><author><name sortKey="Legastelois, Isabelle" sort="Legastelois, Isabelle" uniqKey="Legastelois I" first="Isabelle" last="Legastelois">Isabelle Legastelois</name><affiliation><nlm:affiliation>Department of Research and Development, Sanofi Pasteur, 1541 Avenue Marcel Mérieux, 69280 Marcy L'Etoile, France. Electronic address: isabelle.legastelois@sanofipasteur.com.</nlm:affiliation></affiliation></author><author><name sortKey="Moste, Catherine" sort="Moste, Catherine" uniqKey="Moste C" first="Catherine" last="Moste">Catherine Moste</name><affiliation><nlm:affiliation>Department of Research and Development, Sanofi Pasteur, 1541 Avenue Marcel Mérieux, 69280 Marcy L'Etoile, France. Electronic address: catherine.moste@sanofipasteur.com.</nlm:affiliation></affiliation></author></titleStmt><publicationStmt><idno type="wicri:source">PubMed</idno><date when="2015">2015</date><idno type="RBID">pubmed:26206270</idno><idno type="pmid">26206270</idno><idno type="doi">10.1016/j.vaccine.2015.06.112</idno><idno type="wicri:Area/PubMed/Corpus">000628</idno><idno type="wicri:explorRef" wicri:stream="PubMed" wicri:step="Corpus" wicri:corpus="PubMed">000628</idno></publicationStmt><sourceDesc><biblStruct><analytic><title xml:lang="en">Optimization of influenza A vaccine virus by reverse genetic using chimeric HA and NA genes with an extended PR8 backbone.</title><author><name sortKey="Medina, Julie" sort="Medina, Julie" uniqKey="Medina J" first="Julie" last="Medina">Julie Medina</name><affiliation><nlm:affiliation>Department of Research and Development, Sanofi Pasteur, 1541 Avenue Marcel Mérieux, 69280 Marcy L'Etoile, France. Electronic address: julie.medina@live.fr.</nlm:affiliation></affiliation></author><author><name sortKey="Boukhebza, Houda" sort="Boukhebza, Houda" uniqKey="Boukhebza H" first="Houda" last="Boukhebza">Houda Boukhebza</name><affiliation><nlm:affiliation>Department of Research and Development, Sanofi Pasteur, 1541 Avenue Marcel Mérieux, 69280 Marcy L'Etoile, France. Electronic address: Houda.Boukhebza@sanofipasteur.com.</nlm:affiliation></affiliation></author><author><name sortKey="De Saint Jean, Amelie" sort="De Saint Jean, Amelie" uniqKey="De Saint Jean A" first="Amélie" last="De Saint Jean">Amélie De Saint Jean</name><affiliation><nlm:affiliation>Department of Research and Development, Sanofi Pasteur, 1541 Avenue Marcel Mérieux, 69280 Marcy L'Etoile, France. Electronic address: amelie.desaintjean@free.fr.</nlm:affiliation></affiliation></author><author><name sortKey="Sodoyer, Regis" sort="Sodoyer, Regis" uniqKey="Sodoyer R" first="Régis" last="Sodoyer">Régis Sodoyer</name><affiliation><nlm:affiliation>Department of Research and Development, Sanofi Pasteur, 1541 Avenue Marcel Mérieux, 69280 Marcy L'Etoile, France. Electronic address: regis.sodoyer@bioaster.org.</nlm:affiliation></affiliation></author><author><name sortKey="Legastelois, Isabelle" sort="Legastelois, Isabelle" uniqKey="Legastelois I" first="Isabelle" last="Legastelois">Isabelle Legastelois</name><affiliation><nlm:affiliation>Department of Research and Development, Sanofi Pasteur, 1541 Avenue Marcel Mérieux, 69280 Marcy L'Etoile, France. Electronic address: isabelle.legastelois@sanofipasteur.com.</nlm:affiliation></affiliation></author><author><name sortKey="Moste, Catherine" sort="Moste, Catherine" uniqKey="Moste C" first="Catherine" last="Moste">Catherine Moste</name><affiliation><nlm:affiliation>Department of Research and Development, Sanofi Pasteur, 1541 Avenue Marcel Mérieux, 69280 Marcy L'Etoile, France. Electronic address: catherine.moste@sanofipasteur.com.</nlm:affiliation></affiliation></author></analytic><series><title level="j">Vaccine</title><idno type="eISSN">1873-2518</idno><imprint><date when="2015" type="published">2015</date></imprint></series></biblStruct></sourceDesc></fileDesc><profileDesc><textClass><keywords scheme="KwdEn" xml:lang="en"><term>Amino Acid Sequence</term><term>Animals</term><term>Antigens, Viral (genetics)</term><term>Antigens, Viral (immunology)</term><term>Chlorocebus aethiops</term><term>Dogs</term><term>Hemagglutinin Glycoproteins, Influenza Virus (chemistry)</term><term>Hemagglutinin Glycoproteins, Influenza Virus (genetics)</term><term>Hemagglutinin Glycoproteins, Influenza Virus (immunology)</term><term>Humans</term><term>Influenza A Virus, H1N1 Subtype (genetics)</term><term>Influenza A Virus, H1N1 Subtype (growth & development)</term><term>Influenza A Virus, H1N1 Subtype (immunology)</term><term>Influenza Vaccines (chemistry)</term><term>Influenza Vaccines (genetics)</term><term>Influenza Vaccines (immunology)</term><term>Madin Darby Canine Kidney Cells</term><term>Molecular Sequence Data</term><term>Neuraminidase (genetics)</term><term>Reassortant Viruses (genetics)</term><term>Recombinant Fusion Proteins (chemistry)</term><term>Recombinant Fusion Proteins (immunology)</term><term>Reverse Genetics (methods)</term><term>Sequence Alignment</term><term>Sequence Analysis, DNA</term><term>Vero Cells</term></keywords><keywords scheme="MESH" type="chemical" qualifier="chemistry" xml:lang="en"><term>Hemagglutinin Glycoproteins, Influenza Virus</term><term>Influenza Vaccines</term><term>Recombinant Fusion Proteins</term></keywords><keywords scheme="MESH" type="chemical" qualifier="genetics" xml:lang="en"><term>Antigens, Viral</term><term>Hemagglutinin Glycoproteins, Influenza Virus</term><term>Influenza Vaccines</term><term>Neuraminidase</term></keywords><keywords scheme="MESH" type="chemical" qualifier="immunology" xml:lang="en"><term>Antigens, Viral</term><term>Hemagglutinin Glycoproteins, Influenza Virus</term><term>Influenza Vaccines</term><term>Recombinant Fusion Proteins</term></keywords><keywords scheme="MESH" qualifier="genetics" xml:lang="en"><term>Influenza A Virus, H1N1 Subtype</term><term>Reassortant Viruses</term></keywords><keywords scheme="MESH" qualifier="growth & development" xml:lang="en"><term>Influenza A Virus, H1N1 Subtype</term></keywords><keywords scheme="MESH" qualifier="immunology" xml:lang="en"><term>Influenza A Virus, H1N1 Subtype</term></keywords><keywords scheme="MESH" qualifier="methods" xml:lang="en"><term>Reverse Genetics</term></keywords><keywords scheme="MESH" xml:lang="en"><term>Amino Acid Sequence</term><term>Animals</term><term>Chlorocebus aethiops</term><term>Dogs</term><term>Humans</term><term>Madin Darby Canine Kidney Cells</term><term>Molecular Sequence Data</term><term>Sequence Alignment</term><term>Sequence Analysis, DNA</term><term>Vero Cells</term></keywords></textClass></profileDesc></teiHeader><front><div type="abstract" xml:lang="en">The yield of influenza antigen production may significantly vary between vaccine strains; for example the A/California/07/09 (H1N1)-X179A vaccine virus, prepared during 2009 influenza pandemic, presented a low antigen yield in eggs compared to other seasonal H1N1 reassortants. In this study a bi-chimeric virus expressing HA and NA genes with A/Puerto Rico/8/34 (H1N1) (PR8) and X179A domains was rescued by reverse genetics using a mixture of Vero/CHOK1 cell lines (Medina et al. [7]). The bi-chimeric virus obtained demonstrated to yield much larger amounts of HA than X179A in eggs as measured by single-radial-immunodiffusion (SRID), the reference method to quantify HA protein in influenza vaccine. Such kind of optimized virus using PR8 backbone derived chimeric glycoproteins could be used as improved seed viruses for vaccine production. </div></front></TEI><pubmed><MedlineCitation Status="MEDLINE" Owner="NLM"><PMID Version="1">26206270</PMID><DateCompleted><Year>2016</Year><Month>06</Month><Day>09</Day></DateCompleted><DateRevised><Year>2019</Year><Month>12</Month><Day>10</Day></DateRevised><Article PubModel="Print-Electronic"><Journal><ISSN IssnType="Electronic">1873-2518</ISSN><JournalIssue CitedMedium="Internet"><Volume>33</Volume><Issue>35</Issue><PubDate><Year>2015</Year><Month>Aug</Month><Day>20</Day></PubDate></JournalIssue><Title>Vaccine</Title><ISOAbbreviation>Vaccine</ISOAbbreviation></Journal><ArticleTitle>Optimization of influenza A vaccine virus by reverse genetic using chimeric HA and NA genes with an extended PR8 backbone.</ArticleTitle><Pagination><MedlinePgn>4221-7</MedlinePgn></Pagination><ELocationID EIdType="doi" ValidYN="Y">10.1016/j.vaccine.2015.06.112</ELocationID><ELocationID EIdType="pii" ValidYN="Y">S0264-410X(15)00981-0</ELocationID><Abstract><AbstractText>The yield of influenza antigen production may significantly vary between vaccine strains; for example the A/California/07/09 (H1N1)-X179A vaccine virus, prepared during 2009 influenza pandemic, presented a low antigen yield in eggs compared to other seasonal H1N1 reassortants. In this study a bi-chimeric virus expressing HA and NA genes with A/Puerto Rico/8/34 (H1N1) (PR8) and X179A domains was rescued by reverse genetics using a mixture of Vero/CHOK1 cell lines (Medina et al. [7]). The bi-chimeric virus obtained demonstrated to yield much larger amounts of HA than X179A in eggs as measured by single-radial-immunodiffusion (SRID), the reference method to quantify HA protein in influenza vaccine. Such kind of optimized virus using PR8 backbone derived chimeric glycoproteins could be used as improved seed viruses for vaccine production. </AbstractText><CopyrightInformation>Copyright © 2015 Elsevier Ltd. All rights reserved.</CopyrightInformation></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Medina</LastName><ForeName>Julie</ForeName><Initials>J</Initials><AffiliationInfo><Affiliation>Department of Research and Development, Sanofi Pasteur, 1541 Avenue Marcel Mérieux, 69280 Marcy L'Etoile, France. Electronic address: julie.medina@live.fr.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Boukhebza</LastName><ForeName>Houda</ForeName><Initials>H</Initials><AffiliationInfo><Affiliation>Department of Research and Development, Sanofi Pasteur, 1541 Avenue Marcel Mérieux, 69280 Marcy L'Etoile, France. Electronic address: Houda.Boukhebza@sanofipasteur.com.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>De Saint Jean</LastName><ForeName>Amélie</ForeName><Initials>A</Initials><AffiliationInfo><Affiliation>Department of Research and Development, Sanofi Pasteur, 1541 Avenue Marcel Mérieux, 69280 Marcy L'Etoile, France. Electronic address: amelie.desaintjean@free.fr.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Sodoyer</LastName><ForeName>Régis</ForeName><Initials>R</Initials><AffiliationInfo><Affiliation>Department of Research and Development, Sanofi Pasteur, 1541 Avenue Marcel Mérieux, 69280 Marcy L'Etoile, France. Electronic address: regis.sodoyer@bioaster.org.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Legastelois</LastName><ForeName>Isabelle</ForeName><Initials>I</Initials><AffiliationInfo><Affiliation>Department of Research and Development, Sanofi Pasteur, 1541 Avenue Marcel Mérieux, 69280 Marcy L'Etoile, France. Electronic address: isabelle.legastelois@sanofipasteur.com.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Moste</LastName><ForeName>Catherine</ForeName><Initials>C</Initials><AffiliationInfo><Affiliation>Department of Research and Development, Sanofi Pasteur, 1541 Avenue Marcel Mérieux, 69280 Marcy L'Etoile, France. Electronic address: catherine.moste@sanofipasteur.com.</Affiliation></AffiliationInfo></Author></AuthorList><Language>eng</Language><PublicationTypeList><PublicationType UI="D016428">Journal Article</PublicationType></PublicationTypeList><ArticleDate DateType="Electronic"><Year>2015</Year><Month>07</Month><Day>21</Day></ArticleDate></Article><MedlineJournalInfo><Country>Netherlands</Country><MedlineTA>Vaccine</MedlineTA><NlmUniqueID>8406899</NlmUniqueID><ISSNLinking>0264-410X</ISSNLinking></MedlineJournalInfo><ChemicalList><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D000956">Antigens, Viral</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D019267">Hemagglutinin Glycoproteins, Influenza Virus</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D007252">Influenza Vaccines</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D011993">Recombinant Fusion Proteins</NameOfSubstance></Chemical><Chemical><RegistryNumber>EC 3.2.1.18</RegistryNumber><NameOfSubstance UI="D009439">Neuraminidase</NameOfSubstance></Chemical></ChemicalList><CitationSubset>IM</CitationSubset><MeshHeadingList><MeshHeading><DescriptorName UI="D000595" MajorTopicYN="N">Amino Acid Sequence</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D000818" MajorTopicYN="N">Animals</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D000956" MajorTopicYN="N">Antigens, Viral</DescriptorName><QualifierName UI="Q000235" MajorTopicYN="N">genetics</QualifierName><QualifierName UI="Q000276" MajorTopicYN="N">immunology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D002522" MajorTopicYN="N">Chlorocebus aethiops</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D004285" MajorTopicYN="N">Dogs</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D019267" MajorTopicYN="N">Hemagglutinin Glycoproteins, Influenza Virus</DescriptorName><QualifierName UI="Q000737" MajorTopicYN="N">chemistry</QualifierName><QualifierName UI="Q000235" MajorTopicYN="Y">genetics</QualifierName><QualifierName UI="Q000276" MajorTopicYN="N">immunology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D006801" MajorTopicYN="N">Humans</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D053118" MajorTopicYN="N">Influenza A Virus, H1N1 Subtype</DescriptorName><QualifierName UI="Q000235" MajorTopicYN="Y">genetics</QualifierName><QualifierName UI="Q000254" MajorTopicYN="N">growth & development</QualifierName><QualifierName UI="Q000276" MajorTopicYN="Y">immunology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D007252" MajorTopicYN="N">Influenza Vaccines</DescriptorName><QualifierName UI="Q000737" MajorTopicYN="N">chemistry</QualifierName><QualifierName UI="Q000235" MajorTopicYN="Y">genetics</QualifierName><QualifierName UI="Q000276" MajorTopicYN="Y">immunology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D061985" MajorTopicYN="N">Madin Darby Canine Kidney Cells</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D008969" MajorTopicYN="N">Molecular Sequence Data</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D009439" MajorTopicYN="N">Neuraminidase</DescriptorName><QualifierName UI="Q000235" MajorTopicYN="Y">genetics</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D016865" MajorTopicYN="N">Reassortant Viruses</DescriptorName><QualifierName UI="Q000235" MajorTopicYN="N">genetics</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D011993" MajorTopicYN="N">Recombinant Fusion Proteins</DescriptorName><QualifierName UI="Q000737" MajorTopicYN="N">chemistry</QualifierName><QualifierName UI="Q000276" MajorTopicYN="N">immunology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D059386" MajorTopicYN="N">Reverse Genetics</DescriptorName><QualifierName UI="Q000379" MajorTopicYN="Y">methods</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D016415" MajorTopicYN="N">Sequence Alignment</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D017422" MajorTopicYN="N">Sequence Analysis, DNA</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D014709" MajorTopicYN="N">Vero Cells</DescriptorName></MeshHeading></MeshHeadingList><KeywordList Owner="NOTNLM"><Keyword MajorTopicYN="N">Chimeric</Keyword><Keyword MajorTopicYN="N">Influenza</Keyword><Keyword MajorTopicYN="N">PR8 backbone</Keyword><Keyword MajorTopicYN="N">Vaccine</Keyword></KeywordList></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="received"><Year>2014</Year><Month>09</Month><Day>19</Day></PubMedPubDate><PubMedPubDate PubStatus="revised"><Year>2015</Year><Month>04</Month><Day>06</Day></PubMedPubDate><PubMedPubDate PubStatus="accepted"><Year>2015</Year><Month>06</Month><Day>29</Day></PubMedPubDate><PubMedPubDate PubStatus="entrez"><Year>2015</Year><Month>7</Month><Day>25</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="pubmed"><Year>2015</Year><Month>7</Month><Day>25</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="medline"><Year>2016</Year><Month>6</Month><Day>10</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate></History><PublicationStatus>ppublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">26206270</ArticleId><ArticleId IdType="pii">S0264-410X(15)00981-0</ArticleId><ArticleId IdType="doi">10.1016/j.vaccine.2015.06.112</ArticleId></ArticleIdList></PubmedData></pubmed></record>Pour manipuler ce document sous Unix (Dilib)
EXPLOR_STEP=$WICRI_ROOT/Sante/explor/PandemieGrippaleV1/Data/PubMed/Corpus
HfdSelect -h $EXPLOR_STEP/biblio.hfd -nk 000628 | SxmlIndent | more
Ou
HfdSelect -h $EXPLOR_AREA/Data/PubMed/Corpus/biblio.hfd -nk 000628 | SxmlIndent | more
Pour mettre un lien sur cette page dans le réseau Wicri
{{Explor lien
|wiki= Sante
|area= PandemieGrippaleV1
|flux= PubMed
|étape= Corpus
|type= RBID
|clé= pubmed:26206270
|texte= Optimization of influenza A vaccine virus by reverse genetic using chimeric HA and NA genes with an extended PR8 backbone.
}}
Pour générer des pages wiki
HfdIndexSelect -h $EXPLOR_AREA/Data/PubMed/Corpus/RBID.i -Sk "pubmed:26206270" \
| HfdSelect -Kh $EXPLOR_AREA/Data/PubMed/Corpus/biblio.hfd \
| NlmPubMed2Wicri -a PandemieGrippaleV1
| This area was generated with Dilib version V0.6.34. |  |